Cutler Group LP Provention Bio, Inc. Transaction History

Cutler Group LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	SELL	$6.7 - $24.21 $49,271 - $178,040	-7,354 Reduced 81.99%	1,615 $38,000
Q4 2022 Feb 07, 2023	SELL	$4.52 - $10.57 $19,078 - $44,615	-4,221 Reduced 32.0%	8,969 $94,000
Q2 2022 Aug 04, 2022	BUY	$3.65 - $7.3 $2,920 - $5,840	800 Added 6.46%	13,190 $52,000
Q1 2022 Apr 14, 2022	SELL	$3.4 - $7.88 $680 - $1,576	-200 Reduced 1.59%	12,390 $90,000
Q3 2021 Oct 26, 2021	BUY	$5.66 - $8.33 $46,412 - $68,306	8,200 Added 186.79%	12,590 $80,000
Q2 2021 Jul 19, 2021	BUY	$6.71 - $11.04 $1,342 - $2,208	200 Added 4.77%	4,390 $37,000
Q1 2021 Apr 26, 2021	BUY	$10.12 - $19.45 $27,222 - $52,320	2,690 Added 179.33%	4,190 $43,000
Q4 2020 Jan 21, 2021	BUY	$11.79 - $18.94 $12,968 - $20,834	1,100 Added 275.0%	1,500 $25,000
Q3 2020 Oct 27, 2020	SELL	$10.34 - $15.2 $5,170 - $7,600	-500 Reduced 55.56%	400 $5,000
Q2 2020 Jul 22, 2020	SELL	$7.81 - $17.0 $3,124 - $6,800	-400 Reduced 30.77%	900 $12,000
Q1 2020 May 07, 2020	SELL	$5.42 - $17.75 $13,550 - $44,375	-2,500 Reduced 65.79%	1,300 $11,000
Q3 2019 Oct 28, 2019	BUY	$6.83 - $13.0 $23,222 - $44,200	3,400 Added 850.0%	3,800 $25,000
Q2 2019 Aug 09, 2019	BUY	$2.3 - $13.79 $919 - $5,516	400 New	400 $4,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.